CS
LNAI

Credit Suisse’s Lunai Bioworks LNAI Stock Holding History

Credit Suisse’s Portfolio LNAI Stock Details LNAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Hold
0
– -$1 – 3632
2022
Q4 		– Sell
-3
Closed -$403 – 3921
2022
Q3 		$0 Buy
3
+2
+200% +$365 ﹤0.01% 4244
2022
Q2 		$0 Buy
+1
New +$457 ﹤0.01% 4245

Other funds holding LNAI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
N
Natixis Paris, France $24.8B AUM 35.22% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Credit Suisse's LNAI Position: Q1 2023 in Review

Credit Suisse held its Lunai Bioworks (LNAI) position steady in Q1 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #3632.

Credit Suisse first reported a position in LNAI in Q2 2022 and has held it in 2 quarters since. The position peaked at $0 in Q3 2022. 40 funds tracked by Wall St. Rank hold LNAI as of Q1 2023.

  • Credit Suisse held 0 shares of Lunai Bioworks worth $0 as of Q1 2023.
  • Credit Suisse left its Lunai Bioworks share count unchanged in Q1 2023.
  • Lunai Bioworks made up ﹤0.01% of Credit Suisse's portfolio in Q1 2023, its #3632 holding.
  • Credit Suisse first reported a position in Lunai Bioworks in Q2 2022 and has held it in 2 quarters since.
  • Credit Suisse's Lunai Bioworks position peaked at $0 in Q3 2022.
  • 40 funds tracked by Wall St. Rank held Lunai Bioworks as of Q1 2023.

Based on Credit Suisse's 13F filing for Q1 2023, filed 10 May 2023.